Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

20150288 A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL)

NCT03023878 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03023878
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03023878 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
20150288 A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL)
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
March 13, 2017
Completion date
October 28, 2019
Enrollment
47 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk diffuse large b-cell lymphoma